Most offices won’t touch you.
I’ll tell you when I can.

Short answer: most patients on an oral bisphosphonate for osteoporosis can have dental implants safely. The 2022 AAOMS position paper puts the osteonecrosis-of-the-jaw risk for oral bisphosphonate patients at roughly 0.02 to 0.10% — meaningful but very small. The osteoporosis diagnosis is almost never the disqualifier — the medication is, and only some of them, at some doses, for some durations. I do the work to find out exactly which category you fall into instead of refusing you on sight.

Roughly 1 in 4 women over 65 in the United States lives with osteoporosis, and a large share take a bisphosphonate for it — Fosamax, Actonel, Boniva, Reclast, or the related drug Prolia (denosumab). Most of them have been told at one point or another that they can’t have implants because of the medication. That answer is sometimes right and often wrong, and the difference is the whole reason this page exists. The bigger question of whether you’re a candidate for dental implants turns on more than one medication, and I weigh all of it at the consult.

The concern is osteonecrosis of the jaw (ONJ): a rare condition in which the jaw bone fails to heal after a surgical procedure and exposes non-vital bone. The biology is genuine — bisphosphonates suppress bone turnover, which is normally how the body remodels and repairs bone after trauma. They also quietly reduce blood circulation inside the bone, and blood is what carries the stem cells, growth factors, and infection-fighting white cells a healing implant site depends on. Suppressed turnover plus thinner blood supply means slower healing. In a small subset of patients, it means no healing at all. It is the same blood-supply problem I manage in managing implants with diabetes and in patients who have already lost jaw bone, which is exactly why my UV-plus-PRP protocol matters more here than it does in healthy bone.

But the absolute numbers matter. For oral bisphosphonates taken for osteoporosis prevention under 4 years, ONJ risk after a dental implant is roughly 1 in 10,000 — meaningful but very small. For IV bisphosphonates at oncology doses (Zometa, Aredia), it’s 1–10%, which is a completely different conversation. Lumping both into “you can’t have implants” is lazy medicine. I figure out which category you’re in before I say a word about surgery.

Here is the short version: osteoporotic bone heals slowly and with less blood flow, so the two things I add to every bisphosphonate case — UV-activated titanium and your own PRP — do more here than they do in a healthy mouth. They put blood and bone-building signal back into a site that the medication has quieted down.

Healthy bone heals around an implant in 10–12 weeks. Bisphosphonate-affected bone heals slower because the drug suppresses the osteoclast-osteoblast remodeling cycle. The longer the integration window, the more time the implant sits in a partially-healed wound — which is the actual mechanism for the elevated ONJ risk in this patient population. Closing that window faster is most of how I prevent implant failure in slower-healing bone.

Two interventions shorten that window. UV photofunctionalization restores the surface hydrophilicity of the titanium implant — a property that collapses while titanium sits on a shelf, and which is the single biggest driver of how fast bone cells adhere to the surface. Twelve minutes under a calibrated UV source resets the surface chemistry to the same hydrophilicity as freshly-manufactured titanium. My professor at UCLA, Dr. Ogawa, did the foundational research on this; in his work the UV-activated implant surface roughly doubled the speed and strength of healing and showed 50 to 100 percent more bone-to-implant contact. In osteoporotic bone, that head start is exactly what I want.

Autologous PRP — your own blood, spun and concentrated for platelets — delivers growth factors (PDGF, TGF-β, VEGF) directly to the surgical site. In bisphosphonate-suppressed bone, where the body’s own delivery of those factors is impaired, this matters more than it does in healthy bone. In published studies, controlled osteoporosis — including bisphosphonate use — shows implant survival comparable to non-osteoporotic patients, around 94% at five years; osteonecrosis of the jaw is a rare consideration with bisphosphonates that I screen for. Adding UV and PRP to a slower-healing site is supportive, not a guarantee.